---
document_datetime: 2023-09-21 22:19:51
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_en.pdf
document_name: heplisav-b-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8993582
conversion_datetime: 2025-12-24 20:19:48.823396
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|----------------------------|---------------------------|-------------|
| EU/1/20/1503/001 | HEPLISAV B        | --¹        | Solution for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml (40 µg/ml)         | 5 syringes  |
| EU/1/20/1503/002 | HEPLISAV B        | --¹        | Solution for injection | Intramuscular use         | Pre-filled syringe (glass) | 0.5 ml (40 µg/ml)         | 1 syringe   |

--¹

--¹

One dose (0.5 ml) contains:

Hepatitis B surface antigen¹,²                20 µg

¹Adjuvanted with 3000 micrograms cytidine phosphoguanosine (CpG) 1018 adjuvant, a 22-mer phosphothioate oligonucleotide (PS-ODN) comprising microbial DNA-like unmethylated CpG motifs

²Produced in Hansenula polymorpha yeast cells by recombinant DNA technology